ORLANDO, Fla., Nov. 6 /PRNewswire/ -- A new seven-city study on the impact of new CPR techniques supports the widespread use of the American Heart Association's new 2005 CPR guidelines, according to the study authors in a presentation at the AHA's Scientific Sessions on November 4 in Orlando. Lead author, Tom P. Aufderheide, MD, Professor of Emergency Medicine and Director of the Resuscitation Research Center in the Department of Emergency Medicine at the Medical College of Wisconsin in Milwaukee, presented the data showing a doubling of hospital discharge rates when the AHA's new CPR guidelines were consistently and effectively applied to 893 patients.
The EMS departments submitting data in the study tracked individuals who experienced cardiac arrest outside of the hospital all the way through hospital discharge. When subjects were treated with new CPR techniques including the use of the ResQPOD, an impedance threshold device (ITD), the hospital discharge rates jumped from 7.9 percent to 15.7 percent, or double the survival rate of the control group.
Aufderheide said, "This menu of interventions for patients with cardiac arrest has resulted in one of the highest overall survival rates ever documented for this devastating medical condition. It represents a major breakthrough in the treatment of cardiac arrest, which we hope will be disseminated in other systems throughout the United States."
The seven EMS departments participating in the study used AHA-recommended new CPR including increased compressions, full chest wall recoil and use of the impedance threshold device. The ResQPOD ITD is a $99 device manufactured by Advanced Circulatory Systems (ACS). The impedance threshold device received a Class IIa rating by the AHA in its 2005 Emergency Cardiac Care Guidelines. This is the highest recommendation possible given to an intervention that improves hemodynamics and improves the rate of return of spontaneous circulation after cardiac arrest.
Dr. Keith Lurie, Chief Medical Officer at Advanced Circulatory Systems, said, "There are proven technologies and practices that we know can move the needle to save lives. This is especially true when we use these therapies together. People should not have to rely on being in the right place at the right time when they experience cardiac arrest. While there remains a lot of work to further increase survival rates, the findings from this study, that survival to hospital discharge rates are doubled with this new approach, has great value for all patients who suffer from a cardiac arrest."
More information on Advanced Circulatory Systems and the ResQPOD is available at http://www.advancedcirculatory.com.
The generally cleared indication for the ResQPOD is a temporary increase in blood circulation during emergency care, hospital, clinic and home use. Studies are ongoing in the United States to evaluate the long-term benefit of the ResQPOD for indications related to patients suffering from cardiac arrest, hypotension during dialysis and severe blood loss. The references in this communication are not intended to imply specific outcome-based claims not yet cleared by the US Food and Drug Administration. Clinical study references available upon request.
CONTACT: media, Joanne Henry, +1-612-843-2142, email@example.com,
for ACS; or Keith Lurie, M.D., Chief Medical Officer of ACS,
+1-952-947-9590, firstname.lastname@example.org; or Tom P. Aufderheide,
M.D., FACEP, study lead author, via Tranj Marphetia, +1-414-456-4744,
email@example.com; or Florida medical contact, Laurie Romig, study co-author,
Pinellas County EMS, Largo, Fla., +1-727-582-2202, firstname.lastname@example.org
Web site: http://www.advancedcirculatory.com/